Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV (2015) Am J Respir Crit Care Med 191: 34-44 Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE (2016) Proc Natl Acad Sci U S A 113: E6849-E6858 Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE, Piedra PA, Gilbert BE (2013) MAbs 5: 263-9 Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties. Carroll KN, Griffin MR, Edwards KM, Ali A, Zhu Y, Iwane MK, Szilagyi PG, Staat MA, Stevens TP, Hall CB, Williams JV, Hartert TV (2012) Pediatr Infect Dis J 31: e229-31 Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE (2014) Virology 454-455: 139-44
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.